Alex Biese

Truqap (capivasertib) with fulvestrant has been approved for the treatment of adults with HR-positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations, the FDA announced.

A decade after becoming a bone marrow donor following his brother’s diagnosis of myelofibrosis, former “Queer Eye for the Straight Guy” co-star Thom Filicia is one of the partners behind the Mapping Myelofibrosis initiative.

Patients with colorectal cancer who had diabetes with complications had an 85% higher risk of death than those without diabetes, according to the findings of a study.

Last week’s oncology headlines focused on veterans with cancer, as well as FDA regulatory decisions and an expert’s opinion on what patients need to consider when choosing a Medicare plan.

Researchers found that some caregivers face racism and discrimination as they care for loved ones with cancer.

Up to a quarter of patients with breast cancer face financial burden due to the cost of supplements, complimentary therapy and alternative medicines which “may decrease adherence to prescribed medications,” researchers found.

U.S. Army Reserve Veteran and stage 3 colon cancer survivor discussed the significance of the 2022 passage of the PACT Act and what it means for veterans facing cancer.

Patients with metastatic colorectal cancer are eligible for treatment with Fruzaqla, an oral targeted therapy, following treatment via fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy as well as an anti-VEGF therapy, and, if their disease RAS wild-type and medically appropriate, an anti-EGFR therapy.

Dr. Gene G. Finley spoke about current patient treatment obstacles as part of CURE’s ‘Speaking Out’ video series.

Patients with chronic lymphocytic leukemia are at risk for an increased number and severity of infections due to both their disease and its treatment, an expert explained during the CURE® Educated Patient® CLL Summit.

U.S. veterans face exposures during military service and disparities at home.

Researchers have found that, among patients with relapsed/refractory multiple myeloma who received treatment with the CAR-T cell therapy Abecma, race and ethnicity played roles in safety and response but not survival.

Checking PSA levels following treatment is crucial among patients with nonmetastatic, unfavorable risk prostate cancer, according to the co-author of a recent study.

CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.

Charlene Wexler, the Chicago-based author of the Laughter and Tears series of novels, is an ovarian cancer survivor who now has skin cancer. She told CURE® about how her son’s death from leukemia led to her re-invention as a writer.

Recent research has put a spotlight on a number of factors which could be used to estimate which patients with nonmetastatic, unfavorable-risk prostate cancer are at high risk for a shorter time until PSA recurrence and failure.

Among patients with chondrosarcomas, the most common primary bone tumor in adults, the presence of a TP53 gene mutation has been found to be associated with worse overall survival and metastasis-free survival.

CURE® editors discuss data from the European Society of Medical Oncology Annual Congress, and how it could lead to new therapies being approved.

Amanda Smith, a registered nurse with Huntsman Cancer Institute, explained the impact early satiety can have on patients with MPNs and why communication with their care team is important.

According to the Food and Drug Administration, the shortage of Novartis’ prostate cancer treatment Pluvicto, which began in March, has been resolved, with the manufacturer expecting a continued expansion of supply.

Excellent adherence to hormonal therapy among patients with ductal carcinoma in situ plays a key role in reducing risk of future tumors, researchers found.

Dr. Gene G. Finley of Drexel University of College of Medicine and AHN Cancer Institute, Allegheny Clinic Medical Oncology, explains why the approval of Braftovi and Mektovi “It's an important improvement in our armamentarium.”

One expert explains why palliative care for patients with cancer “is about aligning the patient's goals and the family's goals with the therapeutic goals.”

An expert explains the recent movement towards the use of immunotherapy for patients with resectable NSCLC.

Following the recent FDA approval of Braftovi with Mektovi for some patients with NSCLC and a BRAF V600E mutation, a lung cancer expert explains the science behind the news.

Sally Joy Wolf, who has metastatic breast cancer, tells CURE about how some patients can feel adrift during the annual October “sea of pink.”

“When people see me, they just feel like they have to start jogging,” as one chief nurse practitioner tells CURE when discussing how patients with MPNs can reduce their risk of cardiovascular and thrombotic events.

Researchers found that non-White patients with gastrointestinal cancers, particularly those living in areas with persistent poverty, face inequities in access to and dosage of opioids for end-of-life pain relief.

Patients with cancer and diabetes need to carefully co-manage both diseases, as one expert tells CURE.

A childhood cancer specialist discusses how oncology drug shortages may affect the treatment of children with cancer.